Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

Chadi Nabhan, Lynn M. Rundhaugen, Mary B. Riley, Alfred Rademaker, Larry Boehlke, Mashal Jatoi, Martin S. Tallman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Fingerprint Dive into the research topics of 'Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older'. Together they form a unique fingerprint.

Medicine & Life Sciences